Sandoz Demonstrates Robust Growth in Biosimilar Sales

Sandoz Group AG reported a solid performance in biosimilar sales, with Q3 2026 showing a 17% increase at constant currencies (CC). This progress contributed significantly to the company's net sales during the first nine months of the year. Despite stable generics sales, the firm's strong biosimilar momentum helped total net sales to rise by 5% at CC for both Q3 and the nine-month period. The biosimilar market, particularly in North America, saw a notable 20% growth at CC, underscoring the sector's importance in Sandoz's portfolio.

CEO Richard Saynor emphasized the pivotal role of biosimilars in the company's growth strategy, introducing the "Bio100" ambition that aims for more than 100 biosimilars by 2040. Financially, Sandoz upgraded its core-EBITDA margin guidance, projecting it to reach 23.0-23.5% by year-end 2026. Strategic collaborations and regulatory approvals in various regions further bolster Sandoz's expansive reach in the biosimilars market.